PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6106938

It is appropriate to create new pharmaceutical products within developing countries.

R G Buckles
View original source ↗Export metadata ↓

Abstract

Arguments are presented for utilizing local product development as an appropriate way to solve many of the current medical problems of the Third World. Guidelines for selecting problems amenable to this approach are provided, and the risks attendant on such an activity outlined. It is suggested that organizations such as the World Health Organization can encourage this approach by helping to provide training in product development and by providing consulting services for organizations in the developing world.

Explore related subjects

Developing CountriesDrug IndustryHumansLegislation, PharmacyRiskRural HealthTechnology, PharmaceuticalWorld Health OrganizationJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R G Buckles. 1980-07-28. It is appropriate to create new pharmaceutical products within developing countries.. https://doi.org/10.1098/rspb.1980.0086

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Costs of surgeries in low- and middle-income countries: a systematic literature review.

BACKGROUND: Surgical care is essential for achieving global health equity, yet low- and middle-income countries (LMICs) face major gaps in access and planning, partly due to limited evidence on the costs and resource requirements of surgical interventions. Understanding these costs is vital for designing efficient and equitable health systems. METHODS: We conducted a systematic literature review (covering MEDLINE, EMBASE, Global Health, EconLit and grey literature) to identify studies reporting the costs of surgeries in LMICs from January 2000 to June 2023. Minor and major surgical procedures were considered, focusing on therapeutic procedures (excluding diagnostic interventions). Studies that clearly identified, quantified and costed hospital resources and services deployed in the provision of surgical care, and included at least two of the surgical production factors (ie, consumables, diagnostics, personnel, infrastructure and overhead) in the costing were included. Costs were standardised to 2023 International dollars (I$) for comparability. RESULTS: A total of 74 studies from 29 countries met the inclusion criteria, with 210 cost estimates across 65 procedure groups. Costs varied widely: from I$1.54 for a caesarean section in Tanzania to I$618 098 for paediatric cataract surgery in Zambia. Full costing studies reported higher estimates than partial costing studies. Most studies (60%) originated from upper-middle-income countries, with limited data (10%) from low-income settings. CONCLUSION: This review provides a reference list of surgical procedure costs across LMICs, highlighting considerable cost variation by procedure, specialty and country. The findings underscore the need for better-quality, standardised cost data-especially from low-income countries-to inform national surgical plans, universal health coverage benefit packages and reimbursement policies.

Developing Countries↗